Search results
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look
Guru Focus· 6 days agoOn May 9, 2024, Adverum Biotechnologies Inc (ADVM, Financial), a trailblazer in gene therapy for ocular diseases, disclosed its financial outcomes for the first quarter of 2024 through its 8 ...
AGF Management Ltd. Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 6 hours agoAGF Management Ltd. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the fourth quarter, according to its most recent Form 13F filing with ...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer...
The Grass Valley Union· 3 days agoKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases ...
Clearside Biomedical stock target cut, maintains Buy rating By Investing.com
Investing.com· 3 days agoOn Monday, Clearside Biomedical (NASDAQ:CLSD) saw its price target adjusted by H.C. Wainwright. The...
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
GuruFocus.com via Yahoo Finance· 6 days agoIts flagship product, ADVM-022 (Ixo-vec), aims to revolutionize care for patients with wet age-related macular degeneration (AMD) by ...
Qsemble Capital Management LP Purchases Shares of 239 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 2 days agoQsemble Capital Management LP acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the 4th quarter, according to its most recent 13F filing ...
Why your eye colour might be wrong and 9 other bizarre facts about your peepers
The US Sun· 5 days agoCHANCES are you only really focus on your eyes when there’s something wrong - think nasty infection...
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $46.43 Average Target Price from Analysts
ETF DAILY NEWS· 6 days agoShares of Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat ...